Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 18/20 | 0.64 |
| ▸ | EDNRB | P24530 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314447 | 0.87 | EDNRA (0.65) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL6314270 | 0.79 | EDNRA (0.71) | EDNRAEDNRBKDM4ENSD2TSHR | |
| SCHEMBL6313638 | 0.78 | EDNRA (1.00) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL4201921 | 0.77 | EDNRA (0.98) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL8536257 | 0.76 | EDNRA (0.66) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL8543344 | 0.74 | EDNRA (0.73) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL8060434 | 0.72 | EDNRA (0.72) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL8316284 | 0.71 | ALDH1A1 (0.59) | EDNRAEDNRBKDM4ENSD2TSHR | |
| SCHEMBL4936626 | 0.70 | EDNRA (0.57) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL28416676 | 0.70 | EDNRA (0.60) | EDNRAEDNRBKDM4ENSD2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-0733626-B1 | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | MERCK PATENT GMBH (DE) | 1999-01-13 | — | — | EP | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885KDM4E 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.